Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Consun Pharmaceutical Group Limited (C1P.F)

Compare
0.9100
-0.0600
(-6.19%)
At close: April 4 at 8:05:45 AM GMT+2
Loading Chart for C1P.F
  • Previous Close 0.9700
  • Open 0.9100
  • Bid 0.9200 x --
  • Ask 1.1500 x --
  • Day's Range 0.9100 - 0.9100
  • 52 Week Range 0.0710 - 1.1700
  • Volume 8,350
  • Avg. Volume 350
  • Market Cap (intraday) 890.857M
  • Beta (5Y Monthly) 0.43
  • PE Ratio (TTM) 6.50
  • EPS (TTM) 0.1400
  • Earnings Date Mar 26, 2025
  • Forward Dividend & Yield 0.07 (7.72%)
  • Ex-Dividend Date Jun 10, 2025
  • 1y Target Est --

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

www.chinaconsun.com

3,164

Full Time Employees

December 31

Fiscal Year Ends

Recent News: C1P.F

View More

Performance Overview: C1P.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

C1P.F
11.65%
HANG SENG INDEX (^HSI)
13.91%

1-Year Return

C1P.F
233.77%
HANG SENG INDEX (^HSI)
36.62%

3-Year Return

C1P.F
4,612.20%
HANG SENG INDEX (^HSI)
1.54%

5-Year Return

C1P.F
24,575.95%
HANG SENG INDEX (^HSI)
1.66%

Compare To: C1P.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: C1P.F

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    890.86M

  • Enterprise Value

    443.35M

  • Trailing P/E

    6.71

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.05

  • Price/Book (mrq)

    1.48

  • Enterprise Value/Revenue

    1.20

  • Enterprise Value/EBITDA

    3.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.68%

  • Return on Assets (ttm)

    10.73%

  • Return on Equity (ttm)

    22.07%

  • Revenue (ttm)

    2.97B

  • Net Income Avi to Common (ttm)

    910.46M

  • Diluted EPS (ttm)

    0.1400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.87B

  • Total Debt/Equity (mrq)

    6.08%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: C1P.F

View More

Company Insights: C1P.F

Research Reports: C1P.F

View More

People Also Watch